

0420

1644 #3

I hereby certify that the evidence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: Apr 22, 2002 Signature: [Signature]  
(Name of Signer)

Docket No.: 28967/34891A  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Alitalo, K, et al.

Application No.: 09/765,534

Group Art Unit: 1644

Filed: January 19, 2001

Examiner: TBD

For: Application of: Flt4(VEGFR-3) as a Target for  
Tumor Imaging and Anti-Tumor Therapy

**RECEIVED**  
APR 29 2002  
TECH CENTER 1600/2900

**INFORMATION DISCLOSURE STATEMENT (IDS)**

Commissioner for Patents  
Washington, DC 20231

Dear Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

Copies of the following documents have been enclosed: A27, A28, A29, C1, C13, C15, C24, C37, C38, C40, C47, C64, C66, C67, C68, C78, C83, C84, C91, C93, C94, C96, C97, C99, C108, C113, C114, C116, C124, C138, C145, C158, C163, C164, C167, C171, C185, C198, C201, C204, C207, C208, C214, C226, C237, C244 through C250. The remaining patent(s) or publications not supplied were previously cited by or submitted to the Office in prior application no. 09/169,079, filed October 9, 1998, and relied upon in this application for an earlier filing date under 35 U.S.C. 120.

Most of the items listed on form PTO/SB/08 are provided because they were cited in the specification of this application, in the file wrapper of this application, or in the parent application's case file.

This Information Disclosure Statement is not intended to be an admission that any particular document is "material" pursuant to 37 CFR 1.56, or is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references. In accordance with CFR 1.97(b)(3), no fee is enclosed as the first Office action on the merits has not been mailed.

Dated: April 22, 2002

Respectfully submitted,

By 

David Gass

Registration No.: 38,153

Marshall, Gerstein & Borun  
6300 Sears Tower, 233 South Wacker Drive  
Chicago, IL 60606-6402

Telephone: (312) 474-6300

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

28967/34891A

Serial No.

09/765,534

Applicant

Alitalo, K. *et al.*

Filing Date

January 19, 2001

Group

1644

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	A1	4,543,439	09/24/85	Fracketton, Jr. <i>et al.</i>	435	70.21	
	A2	4,652,639	03/24/87	Stabinsky	536	27	
	A3	4,933,294	06/12/90	Waterfield <i>et al.</i>	436	501	
	A4	5,183,884	02/02/93	Kraus <i>et al.</i>	536	23.5	
	A5	5,185,438	02/09/93	Lemischka	536	23.2	
	A6	5,198,359	03/30/93	Taniguchi <i>et al.</i>	435	252.3	
	A7	5,231,001	07/27/93	Kaplan <i>et al.</i>	435	7.21	
	A8	5,256,766	10/26/93	Coughlin	530	327	
	A9	5,270,458	12/14/93	Lemischka	536	23.5	
	A10	5,283,354	02/01/94	Lemischka	536	23.5	
	A11	5,367,057	11/22/94	Lemischka	530	350	
	A12	5,635,177	06/03/97	Bennett <i>et al.</i>	424	143.1	
	A13	5,643,759	07/01/97	Pfreundschuh, M.	435	70.21	
	A14	5,693,762	12/02/97	Queen, C.L. <i>et al.</i>	530	387.3	
	A15	5,700,822	12/23/97	Hirth, K.P. <i>et al.</i>	514	380	
	A16	5,712,395	01/27/98	App, H. <i>et al.</i>	544	344	
	A17	5,747,651	05/05/98	Lemischka, I.R.	530	387.9	
	A18	5,750,078	05/12/98	Shitara, K. <i>et al.</i>	424	133.1	
	A19	5,763,441	06/09/98	App, H. <i>et al.</i>	514	249	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

APR 26 2002

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
28967/34891ASerial No.  
09/765,534Applicant  
Alitalo, K. *et al.*Filing Date  
January 19, 2001Group  
1644

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

RECEIVED

APR 29 2002

TECH CENTER 1600/2900

## U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	A20	5,763,733	06/09/98	Whitlow, M. <i>et al.</i>	530	387.3	
	A21	5,776,427	07/07/98	Thorpe, P.E. <i>et al.</i>	424	1.49	
	A22	5,776,755	07/07/98	Alitalo, K. <i>et al.</i>	435	194	
	A23	5,798,097	08/25/98	McKenzie, I.F.C. <i>et al.</i>	424	181.1	
	A24	5,807,548	09/15/98	Shitara, K. <i>et al.</i>	424	133.1	
	A25	5,952,199	09/14/99	Davis-Smyth <i>et al.</i>	435	69.7	
	A26	6,011,003	01/04/00	Charnock-Jones <i>et al.</i>	514	2	
	A27	6,107,046	08/22/00	Alitalo, K. <i>et al.</i>	435	7.1	
	A28	6,130,071	10/10/00	Alitalo, K. <i>et al.</i>	435	69.4	
	A29	6,331,302	12/18/01	Bennett, <i>et al.</i>	424	146.1	


## FOREIGN PATENT DOCUMENTS

*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No
	B1	EP 0 325 224 A2	07/26/89	EPO				
	B2	WO 90/14425	11/29/90	WIPO				
	B3	WO 92/13867	08/20/92	WIPO				
	B4	WO 92/14748	03/09/92	WIPO				

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 28967/34891A	Serial No. 09/765,534
<b>INFORMATION DISCLOSURE STATEMENT</b> <i>(Use several sheets if necessary)</i>			Applicant Alitalo, K. <i>et al.</i>	
			Filing Date January 19, 2001	Group 1644

## FOREIGN PATENT DOCUMENTS

*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No
	B5	WO 93/14124	07/22/93	WIPO				
	B6	WO 93/15201	08/05/93	WIPO				
	B7	WO 94/10202	05/11/94	WIPO				
	B8	WO 95/24473	09/14/95	WIPO				
	B9	WO 95/33772	12/14/95	WIPO				
	B10	WO 96/39515	12/12/96	WIPO				
	B11	WO 97/05250	02/13/97	WIPO				
	B12	WO 97/09427	03/13/97	WIPO				
	B13	WO 98/33917	08/06/98	WIPO				
	B14	98/07832	26/02/98	WO	6			
	B15	99/33485	08/07/99	WO	6			

RECEIVED

APR 29 2002

TECH CENTER 1600/2900

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C1	Achen, M. G., <i>et al.</i> , "Localization of Vascular Endothelial Growth Factor-D in Malignant Melanoma Suggests a Role in Tumour Angiogenesis," J. Pathol. 193(2): 147-54 (2001).
C2	Achen, M.G. <i>et al.</i> , "Monoclonal antibodies to vascular endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3," <i>Eur. J. Biochem.</i> 267(9):2505-15 (May, 2000).

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
28967/34891ASerial No.  
09/765,554Applicant  
Alitalo, K. *et al.*Filing Date  
January 19, 2001Group  
1644

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C3	Achen, M.G. <i>et al.</i> , "Vascular endothelial growth factor D (VEGF-F) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)," <i>Proc. Natl. Acad. Sci., USA</i> , 95(2):548-553 (January, 1998).
C4	Akagi, K., <i>et al.</i> , "Vascular endothelial growth factor-C (VEGF-C) expression in colorectal cancer tissues," <i>Br. J. Cancer</i> , 83(7):887-91 (October, 2000).
C5	Andre, T., <i>et al.</i> , "Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FL the neoplastic progression of human colonic mucosa," <i>Int. J. Cancer</i> , 86(2):174-81 (April 15, 2000).
C6	Andersson <i>et al.</i> , "Structural and Functional Markers During Induced Differentiation in Human Leukemia Cell Lines," <i>In R. F. Revoltella (ed.), Expression of Differentiated Functions in Cancer Cells</i> . 239-245, Raven Press, New York (1982).
C7	"Angiogenesis Inhibitors in Cancer Research," <i>Cancer Trials</i> , at <a href="http://cancertrials.nci.nih.gov/news/angio/fsangio/fsangio.html">cancertrials.nci.nih.gov/news/angio/fsangio/fsangio.html</a> (visited Jan. 24, 2001).
C8	"Angiogenesis Inhibitors in Clinical Trials," <i>Cancer Trials</i> , at <a href="http://cancertrials.nci.nih.gov/news/angio/table.html">cancertrials.nci.nih.gov/news/angio/table.html</a> (visited Jan. 24, 2001).
C9	"Angiogenesis Inhibitors in Clinical Trials," <i>Cancer Trials</i> , at <a href="http://cancertrials.nci.nih.gov/news/angio/table.html">cancertrials.nci.nih.gov/news/angio/table.html</a> (visited Sep. 25, 2001).
C10	"Angiogenesis Inhibitors in Clinical Trials: Expanded Trial Information," <i>Cancer Trials</i> , at <a href="http://cancertrials.nci.nih.gov/news/angio/table.html">cancertrials.nci.nih.gov/news/angio/table.html</a> (visited Sep. 25, 2001).
C11	Aprelikova <i>et al.</i> , "FLT4, A Novel Class III Receptor Tyrosine Kinase in Chromosome 5q33-qter," <i>Cancer Research</i> , 52(3):746-748 (February 1, 1992).
C12	Aujame, L. <i>et al.</i> , "High affinity human antibodies by phage display," <i>Human Antibodies</i> , 8(4):155-168 (1997).
C13	Banerji, S. <i>et al.</i> , "LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan," <i>J Cell Biol.</i> 144(4):789-801 (1999).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

28967/34891A

Serial No.

09/765,534

Applicant

Alitalo, K. *et al.*

Filing Date


January 19, 2001

Group

1644

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)



RECEIVED

APR 29 2002

TECH CENTER 600/2900


## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C14	Beckstead, J.H. <i>et al.</i> , "Evidence for the Origin of Kaposi's Sarcoma From Lymphatic Endothelium," <i>Am. J. Pathol.</i> , 119(2):294-300 (May, 1985).
C15 ✓	Benz, C. C. <i>et al.</i> , "Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu," <i>Breast Cancer Res Treat.</i> 24(2):85-95 (1993). ✓ 16
C16	Berridge <i>et al.</i> , "Cell-Lineage Antigens of the Stem Cell-Megakaryocyte-Platelet Linkage are Associated with the Platelet IIb-IIIa Glycoprotein Complex," <i>Blood</i> , 66(1):76-85 (July, 1985).
C17	Bolen, J.B., "Nonreceptor Tyrosine Protein Kinases," <i>Oncogene</i> , 8:2025-2031 (1993).
C18	Bolhuis, R.L. <i>et al.</i> , "T cell targeting in cancer therapy," <i>Cancer Immunology Immunotherapy</i> , 34(1):1-8 (1991).
C19	Borg <i>et al.</i> , "Biochemical Characterization of Two Isoforms of FLT4, a VEGF Receptor-Related Tyrosin Kinase," <i>Oncogene</i> , 10:973-984 (1995).
C20	Brown, L.F. <i>et al.</i> , "Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) and Its Receptors in Breast Cancer," <i>Human Pathology</i> , 26(1):86-91 (January, 1995).
C21	Brüggemann, M. <i>et al.</i> , "Production of human antibody repertoires in transgenic mice," <i>Curr. Opin. Biotechnol.</i> , 8:455-458 (1997).
C22	Brüggemann, M. <i>et al.</i> , "Strategies for expressing human antibody repertoires in transgenic mice," <i>Immunol. Today</i> , 17(8):391-397 (August, 1996).
C23	Bunone, G., <i>et al.</i> , "Expression of Angiogenesis Stimulators and Inhibitors in Human Thyroid Tumors and Correlation with Clinical Pathological Features," <i>Am. J. Pathol.</i> , 155(6):1967-76 (December 1999).
C24 ✓	Byrne, C. <i>et al.</i> , "Programming Gene Expression in Developing Epidermis," <i>Development</i> , 120(9):2369-83 (1994).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 28967/34891A	Serial No. 09/765,534
<b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)			Applicant Alitalo, K. <i>et al.</i>	
			Filing Date January 19, 2001	Group 1644

RECEIVED  
 APR 29 2002  
 TECH CENTER 1600/2900

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
C25	Cantley <i>et al.</i> , "Oncogenes and Signal Transduction," <i>Cell</i> , 64:281-302 (January 25, 1991).	
C26	Cao, Y., <i>et al.</i> , "Vascular Endothelial Growth Factor C Induces Angiogenesis <i>in Vivo</i> ," <i>Proc. Natl. Acad. Sci. USA</i> , 95:14389-94 (November 1998).	
C27	Carter, P. <i>et al.</i> , "Toward the Production of Bispecific Antibody Fragments for Clinical Applications," <i>Journal of Hematotherapy</i> , 4:463-470 (1995).	
C28	Catoretti <i>et al.</i> , "Monoclonal Antibodies Against Recombinant Parts of the Ki-67 Antigen (MIB 1 and MIB 3) Detect Proliferating Cells in Microwave-Processed Formalin-Fixed Paraffin Section," <i>J. of Pathol.</i> , 168:357-363 (1992).	
C29	Cheng & Flanagan, "Identification and Cloning of ELF-1, a Developmentally Expressed Ligand for the Mek4 and Sek Receptor Tyrosine Kinases," <i>Cell</i> , 79:157-168 (October 7, 1994).	
C30	Cole <i>et al.</i> , "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer," <i>Monoclonal Antibodies and Cancer Therapy</i> , Alan R Liss, Inc., pp. 77-96 (1985).	
C31	Collins <i>et al.</i> , "Continuous Growth and Differentiation of Human Myeloid Leukaemic Cells in Suspension Culture," <i>Nature</i> , 270:347-349 (1977).	
C32	De Gast, G.C. <i>et al.</i> , "Clinical perspectives of bispecific antibodies in cancer," <i>Cancer Immunol Immunother</i> , 45:121-123 (1997).	
C33	De Vries <i>et al.</i> , "The <i>fms</i> -Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor," <i>Science</i> , 255:989-991 (February 21, 1992).	
C34	De Waal, R. <i>et al.</i> , "Technical Advance: Lack of Lymphangiogenesis in Human Primary Cutaneous Melanoma," <i>American Journal of Pathology</i> , 150(6):1951-1957 (June, 1997).	
C35	Devereux <i>et al.</i> , "A Comprehensive Set of Sequence Analysis Programs for the VAX," <i>Nucleic Acids Res.</i> , 12(1):387-395 (1984).	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
28967/34891ASerial No.  
09/765,534Applicant  
Alitalo, K. *et al.*Filing Date  
January 19, 2001Group  
1644

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

RECEIVED

APR 29 2002

TECH CENTER 1600/2900

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C36	Dictor, M. <i>et al.</i> , "Lymphaticovenous Differentiation in Kaposi's Sarcoma: Cellular Phenotypes by Stage," <i>American Journal of Pathology</i> , 130(2):411-417 (February, 1988).
C37	Dignam <i>et al.</i> , "Balbiani Ring 3 in Chironomus Tentans Encodes a 185-kDa Secretory Protein Which Is Synthesized Throughout the Fourth Larval Instar," <i>Gene</i> , 88:133-40 (1990).
C38	Dumont, D. J. <i>et al.</i> , "Cardiovascular Failure in Mouse Embryos Deficient in VEGF Receptor-3," <i>Science</i> , 282(5390):946-49 (1998).
C39	Edgell <i>et al.</i> , "Permanent Cell Line Expressing Human Factor VIII-Related Antigen Established by Hybridization," <i>Proc. Nat'l. Acad. Sci. USA</i> , 50:3734-3737 (June, 1983).
C40	Egeblad, M. and Jaattela, M. "Cell death induced by TNF or serum starvation is independent of ErbB receptor signaling in MCF-7 breast carcinoma cells," <i>Int J Cancer</i> , 86(5):617-25 (2000).
C41	Eggert, A., <i>et al.</i> , "High-Level Expression of Angiogenic Factors Is Associated with Advanced Tumor Stage in Human Neuroblastomas," <i>Clin. Cancer Res.</i> , 6(5):1900-8 (May 2000).
C42	Eichmann <i>et al.</i> , "Molecular cloning of Quek 1 and 2, two quail vascular endothelial growth factor (VEGF) receptor-like molecules," <i>Gene</i> , 174(1):3-8 (1996).
C43	Enholm, B. <i>et al.</i> , "Vascular Endothelial Growth Factor-C, a Growth Factor for Lymphatic and Blood Vascular Endothelial Cells," <i>TCM</i> , 8(7):292-297 (1998).
C44	Fanger, M.W. <i>et al.</i> , "Bispecific Antibodies," <i>Critical Reviews in Immunology</i> , 12(3,4):101-124 (1992).
C45	Fellmer, P.T., <i>et al.</i> , "Vascular endothelial growth factor-C gene expression in papillary and follicular thyroid carcinomas," <i>Surgery</i> , 126(6):1056-61 (December 1999).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
28967/34891ASerial No.  
09/765,534Applicant  
Alitalo, K. *et al.*Filing Date  
January 19, 2001Group  
1644

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)


## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C46	Ferrara, N. <i>et al.</i> , "The Biology of Vascular Endothelial Growth Factor," <i>Endocrine Reviews</i> , 18(1):4-25 (1997).
C47	Ferrara, N. <i>et al.</i> , "Molecular and Biological Properties of Vascular Endothelial Growth Factor," <i>J Mol Med.</i> , 77(7):527-43. (1999).
C48	Fielder W., <i>et al.</i> , "Expression of FLT4 and its ligand VEGF-C in Acute Myeloid Leukemia," <i>Leukemia</i> , 8:1234-7 (August 1997) (Abstract).
C49	Finnerty <i>et al.</i> , "Molecular Cloning g of Murine FLT and FLT4," <i>Oncogene</i> , 8(11):2293-2298 (1993).
C50	Flanagan & Leder, "The <i>kit</i> Ligand: A Cell Surface Molecule Altered in Steel Mutant Fibroblasts," <i>Cell</i> , 63:185-194 (October 5, 1990).
C51	Folkman <i>et al.</i> , "Long-term culture of capillary endothelial cells," <i>Proc. Nat'l Acad. Sci., USA</i> , 76(10):5217-5221 (October, 1979).
C52	Folpe, A.L., <i>et al.</i> , "Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3): A Marker of Vascular Tumors with Presumed Lymphatic Differentiation, Including Kaposi's Sarcoma, Kaposiform and Dabska-Type Hemangioendotheliomas, and a Subset of Angiosarcomas," <i>Mod. Pathol</i> , 13(2):180-185 (2000).
C53	Foote, J. <i>et al.</i> , "Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops," <i>J. Mol. Biol.</i> , 224:487-499 (1992).
C54	Fortkamp <i>et al.</i> , "Cloning and Expression in <i>Escherichia coli</i> of a Synthetic DNA for Hirudin, the Blood Coagulation Inhibitor in the Leech," <i>DNA</i> , 5(6):511-517 (1986).
C55	Fournier <i>et al.</i> , "Mutation at Tyrosine Residue 1337 Abrogates Ligand-Dependent Transforming Capacity of the FLT4 Receptor," <i>Oncogene</i> , 11:921-931 (1995).
C56	Fournier <i>et al.</i> , "Interaction with the Phosphotyrosine Binding Domain/Phosphotyrosine Interacting Domain of SHC Is Required for the Transforming Activity of the FLT4/VEGFR3 Receptor Tyrosine Kinase," <i>J. Biological Chemistry</i> , 271(22):12956-12963 (1996).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 28967/34891A	Serial No. 09/765,534
<b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)			Applicant Alitalo, K. <i>et al.</i>	
			Filing Date January 19, 2001	Group 1644

RECEIVED

APR 26 2002

TECH CENTER 1600/2900

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
C57	Gahmberg <i>et al.</i> , "Membrane Glycolysation During Cell Differentiation," <i>In</i> L. C. Andersson, <i>et al.</i> (ed.), <i>Gene Expression During Normal and Malignant Differentiation</i> , 107-123, Academic Press, London (1985).	
C58	Galland <i>et al.</i> , "Chromosomal Localization of FLT4, a Novel Receptor-Type Tyrosine Kinase Gene," <i>Genomics</i> , 13:475-478 (1992).	
C59	Galland <i>et al.</i> , "The FLT4 Gene Encodes a Transmembrane Tyrosine Kinase Related to the Vascular Endothelial Growth Factor Receptor," <i>Oncogene</i> , 8(11):1233-1240 (1993).	
C60	Gasparini, G. <i>et al.</i> , "Clinical Importance of the Determination of Tumor Angiogenesis in Breast Carcinoma: Much More Than a New Prognostic Tool," <i>Journal of Clinical Oncology</i> , 13(3):765-782 (March, 1995).	
C61	Genbank Accession X51602 Human flt mRNA for receptor-related tyrosine kinase, deposited by Shibuya, M.	
C62	Genbank Accession X60280 plasmid pLTRpoly, deposited by Maekelae <i>et al.</i>	
C63	Genbank Accession X68203 H. sapiens mRNA for FLT4, Class III receptor tyrosine kinase, deposited by Aprelikova, O.	
C64	Genbank Accession X83287 C. coturnix Quek2 mRNA for vascular endothelial growth factor receptor, deposited by Eichmann, <i>et al.</i>	
C64	GenBank Accession No. AF014827, Rattus norvegicus vascular endothelial growth factor D (VEGF-D) mRNA, deposited by Yamada, Y.	
C65	GenBank Accession No. AJ000185, Homo Sapiens mRNA for vascular endothelial growth factor-D, deposited by Achen, M.G.	
C66	GenBank Accession No. CCY15837, Coturnix coturnix mRNA for vascular endothelial growth factor C, deposited by Eichmann, A.	
C67	GenBank Accession No. D89628, Mus musculus mRNA for vascular endothelial growth factor D, deposited by Yamada, Y.	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
28967/34891ASerial No.  
09/765,534Applicant  
Alitalo, K. *et al.*Filing Date  
January 19, 2001Group  
1644

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C68	GenBank Accession No. MMU73620, Mus musculus VEGF-C mRNA, complete cds., deposited by Kukke, E.
C69	Greenberg <i>et al.</i> , "Characterization of a New Megakaryocyte Cell Line: The Dami Cell," <i>Blood</i> , 72(6):1968-1977 (December, 1988).
C70	Gunningham, S.P., <i>et al.</i> , "The Short Form of the Alternatively Spliced <i>flt-4</i> but not Its Ligand Vascular Endothelial Growth Factor C Is Related to Lymph Node Metastasis in Human Breast Cancers," <i>Clin. Cancer Res.</i> , 6(11):4278-86 (November 2000).
C71	Harlow <i>et al.</i> , <i>Antibodies: A Laboratory Manual</i> , pp.7-25, 72-137, 141-157, 287 & 321-358 (1988).
C72	Hatva <i>et al.</i> , "Expression of Endothelial Cell-Specific Receptor Tyrosine Kinases and Growth Factors in Human Brain Tumors," <i>Am. J. Pathol.</i> , 146:368-378 (1995).
C73	Hatva, E., <i>et al.</i> , "Vascular Growth Factors and Receptors in Capillary Hemangioblastomas and Hemangiopericytomas," <i>Am. J. Pathol.</i> , 148(3):763-75 (March 1996).
C74	Heldin <i>et al.</i> , "Platelet-Derived Growth Factor: Mechanism of Action and Possible <i>in Vivo</i> Function," <i>Cell Regulation</i> , 1:555-566 (July, 1990).
C75	Hemmila <i>et al.</i> , "Europium as a Label in Time-Resolved Immunofluorometric Assays," <i>Annal. Biochem.</i> , 137:335-343 (1984).
C76	Hewett, P.W. <i>et al.</i> , "Coexpression of <i>flt-1</i> , <i>flt-4</i> and KDR in Freshly Isolated and Cultured Human Endothelial Cells," <i>Biochemical and Biophysical Research Communications</i> , 221:697-702 (1996).
C77	Hirai <i>et al.</i> , "A Novel Putative Tyrosine Kinase Receptor Encoded by the <i>eph</i> Gene," <i>Science</i> , 238:1717-1720 (1987).
C78	Hirai, M. <i>et al.</i> , "Expression of Vascular Endothelial Growth Factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in Postmenopausal Uterine Endometrial Carcinoma," <i>Gynecol. Oncol.</i> 80(2):181-8 (February, 2001).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

28967/34891A

Serial No.

09/765,534

Applicant

Alitalo, K. *et al.*

Filing Date


January 19, 2001

Group

1644

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)



RECEIVED

APR 29 2002

TECH CENTER 1600/2900

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C79	Hoogenboom, H.R., "Designing and optimizing library selection strategies for generating high-affinity antibodies," <i>TIBTECH</i> , 15:62-70 (1997).
C80	Hu; Jing-Shan, <i>et al.</i> , "A Novel Regulatory Function of Proteolytically Cleaved VEGF-2 for Vascular Endothelial and Smooth Muscle Cells," <i>The FASEB Journal</i> , 11:498-504 (May 1997).
C81	Huang <i>et al.</i> , "The Hematopoietic Growth Factor KL is Encoded by the <i>SI</i> Locus and is the Ligand of the <i>c-kit</i> Receptor, the Gene Product of the <i>W</i> Locus," <i>Cell</i> , 63:225-33 (October 5, 1990).
C82	Hunter & Greenwood, "Preparation of Iodine-131 Labelled Human Growth Hormone of High Specific Activity," <i>Nature</i> , 194(4827):495-496 (May 5, 1962).
C83	IMC-1C11, ImClone Systems Incorporated, at <a href="http://www.imclone.com/imc1c11.html">www.imclone.com/imc1c11.html</a> (visited Sep. 25, 2001).
C84	Irrthum, A. <i>et al.</i> , "Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase.," <i>Am J Hum Genet.</i> 67(2):295-301 (2000).
C85	Jacquemier, J., <i>et al.</i> , "Prognosis of Breast-Carcinoma Lymphagenesis Evaluated by Immunohistochemical Investigation of Vascular-Endothelial-Growth-Factor Receptor 3," <i>Int. J. Cancer (Pred. Oncol.)</i> , 89:69-73 (2000).
C86	Jeltsch, "Hyperplasia of Lymphatic Vessels in VEGF-C Transgenic Mice," <i>Science</i> , 276:1423-1425 (May 30, 1997).
C87	Jones, A., <i>et al.</i> , "Angiogenesis and lymphangiogenesis in stage 1 germ cell tumours of the testis," <i>BJU International</i> , 86:80-86 (2000).
C88	Jones, P.T. <i>et al.</i> , "Replacing the complementarity-determining regions in a human antibody with those from a mouse," <i>Nature</i> , 321:522-525 (May, 1986).
C89	Joukov <i>et al.</i> , "A Novel Vascular Endothelial Growth Factor, VEGF-C, is a Ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) Receptor Tyrosine Kinases," <i>EMBO J.</i> , 15(2):290-298 (January 15, 1996).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

28967/34891A

Serial No.

09/765,534

Applicant

Alitalo, K. *et al.*

Filing Date


January 19, 2001

Group

1644

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)



RECEIVED

APR 29 2002

TECH CENTER 1600/2000

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C90	Joukov, V. <i>et al.</i> , "Proteolytic processing regulates receptor specificity and activity of VEGF-C," <i>EMBO Journal</i> , 16(13):3898-3911 (June, 1997).
C91	Joukov, V. <i>et al.</i> , "A Recombinant Mutant Vascular Endothelial Growth Factor-c That Has Lost Vascular Endothelial Growth Factor Receptor-2 Binding, Activation, and Vascular Permeability Activities," <i>J Biol Chem.</i> , 273(12):6599-602 (1998).
C92	Jussila, L. <i>et al.</i> , "Lymphatic Endothelium and Kaposi's Sarcoma Spindle Cells Detected by Antibodies against the Vascular Endothelial Growth Factor Receptor-3," <i>Cancer Res.</i> , 58:1599-1604 (April, 1998).
C93	Kabashima, A. <i>et al.</i> , "Overexpression of Vascular Endothelial Growth Factor C is Related to Lymphogenous Metasasis in Early Gastric Carcinoma," <i>Oncology</i> , 60(2): 146-50 (2001)
C94	Kadambi, A. <i>et al.</i> , "Vascular Endothelial Growth Factor (VEGF)-C Differentially Affects Tumor Vascular Function and Leukocyte Recruitment: Role of VEGF-Receptor 2 and Host VEGF-A," <i>Cancer Res.</i> 61(6): 2404-8 (March, 2001).
C95	Kaipainen <i>et al.</i> , "Expression of the FMS-Like Tyrosine Kinase 4 Gene Becomes Restricted to Lymphatic Endothelium During Development," <i>Proc. Nat'l Acad. Sci., USA</i> , 92:3566-3570 (April, 1995).
C96	Kaipainen <i>et al.</i> , "The Related FLT4, FLT1, and KDR Receptor Tyrosine Kinases Show Distinct Expression Patterns in Human Fetal Endothelial Cells," <i>J. Exp. Med.</i> , 178:2077-2088 (December, 1993).
C97	Karkkainen, <i>et al.</i> , "Missense Mutations Interfere With VEGFR-3 Signalling in Primary Lymphoedema," <i>Nat Genet.</i> , 25(2):153-9 (2000).
C98	Karkkainen, M.J., <i>et al.</i> , "Vascular Endothelial Growth Factor Receptors in the Regulation of Angiogenesis and Lymphangiogenesis," <i>Oncogene</i> , 19(49):5598-605 (November 20, 2000).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

28967/34891A

Serial No.

09/765,534

Applicant

Alitalo, K. *et al.*

Filing Date

January 19, 2001

Group

1644

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C99	Karpanen, T. <i>et al.</i> , "Vascular Endothelial Growth Factor C Promotes Tumor Lymphangiogenesis and Intralymphatic Tumor Growth," <i>Cancer Res.</i> 61(5): 1786-90 (March, 2001).
C100	Kerstens, H. <i>et al.</i> , "A Novel In Situ Hybridization Signal Amplification Method Based on the Deposition of Biotinylated Tyramine," <i>Journal Histochemistry and Cytochemistry</i> , 43(4):347-352 (1995).
C101	Kettleborough, C.A. <i>et al.</i> , "Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation," <i>Protein Engineering</i> , 4(7):773-783 (1991).
C102	Kieffer <i>et al.</i> , "Uncoupling in the Expression of Platelet GP IIb/IIIa in Human Endothelial Cells and K562 Cells: Absence of Immunologic Crossreactivity Between Platelet GP IIb and the Vitronectin Receptor Alpha Chain," <i>Blood</i> , 72(4):1209-1215 (October, 1988).
C103	Kim, K.J. <i>et al.</i> , "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth <i>in vivo</i> ," <i>Nature</i> , 362(6423):841-844 (April, 1993).
C104	Koeffler <i>et al.</i> , "Acute Myelogenous Leukemia: A Human Cell Line Responsive to Colony-Stimulating Activity," <i>Science</i> , 200:1153-1154 (1978).
C105	Köhler <i>et al.</i> , "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity," <i>Nature</i> , 256:495-497 (August 7, 1975).
C106	Korhonen <i>et al.</i> , "Enhanced Expression of the <i>tie</i> Receptor Tyrosine Kinase in Endothelial Cells During Neovascularization," <i>Blood</i> , 80(10):2548-2555 (November 15, 1992).
C107	Korhonen <i>et al.</i> , "The Mouse Tie Receptor Tyrosine Kinase Gene: Expression During Embryonic Angiogenesis," <i>Oncogene (England)</i> , 9(2):395-403 (February, 1994).
C108	Korhonen, J. <i>et al.</i> , "Endothelial-Specific Gene Expression Directed by the Tie Gene Promoter <i>in Vivo</i> ," <i>Blood</i> (5):1828-35 (1995).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
28967/34891ASerial No.  
09/765,534Applicant  
Alitalo, K. *et al.*Filing Date  
January 19, 2001Group  
1644

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

RECEIVED

APR 29 2002

TECH CENTER 1600/2900

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C109	Kozbor <i>et al.</i> , "The Production of Monoclonal Antibodies From Human Lymphocytes," <i>Immunology Today</i> , 4(3):72-79 (1983).
C110	Kubo, H., <i>et al.</i> , "Involvement of Vascular Endothelial Growth Factor Receptor-3 in Maintenance of Integrity of Endothelial Cell Lining During Tumor Angiogenesis," <i>Blood</i> , 96(2):546-553 (15 July 2000).
C111	Kukk <i>et al.</i> , "VEGF-C Receptor Binding and Pattern of Expression with VEGFR-3 Suggests A Role in Lymphatic Vascular Development," <i>Development</i> , 122:3829-3837 (December, 1996).
C112	Kurebayashi, J., <i>et al.</i> , "Expression of Vascular Endothelial Growth Factor (VEGF) Family Members in Breast Cancer," <i>Jpn. J. Cancer Res.</i> , 90(9):977-81 (September 1999).
C113	Laitinen, M. <i>et al.</i> , "Adenovirus-mediated Gene Transfer to Lower Limb Artery of Patients With Chronic Critical Leg Ischemia," <i>Hum Gene Ther</i> , 9(10):1481-6 (1998).
C114	Lauria, R. <i>et al.</i> , "The Prognostic Value of Lymphatic and Blood Vessel Invasion in Operable Breast Cancer," <i>Cancer</i> , 76(10):1772-8 (1995).
C115	Lee <i>et al.</i> , "Vascular Endothelial Growth Factor-Related Protein: A Ligand and Specific Activator of the Tyrosine Kinase Receptor Flt4," <i>Proc. Natl. Acad. Sci., USA</i> , 93:1988-1992 (March, 1996).
C116	Leu, A. J. <i>et al.</i> , "Absence of Functional Lymphatics within a Murine Sarcoma: A Molecular and Functional Evaluation," <i>Cancer Res</i> , 60: 4324-7, (2000).
C117	Lhotak <i>et al.</i> , "Characterization of Elk, a Brain-Specific Receptor Tyrosine Kinase," <i>Mol. Cell. Biol.</i> , 11:2496-2502 (May, 1991).
C118	Lindberg <i>et al.</i> "cDNA Cloning and Characterization of <i>eck</i> , an Epithelial Cell Receptor Protein-Tyrosine Kinase in the <i>eph/elk</i> Family of Protein Kinases," <i>Mol. Cell. Biol.</i> , 10:6316-6324 (December, 1990).
C119	Lovgren <i>et al.</i> , "Time-Resolved Fluorometry in Immunoassay," <i>In: Collins W.P. (Ed.) Alternative Immunoassays</i> , John Wiley & Sons Ltd., pp.203-217 (1985).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

28967/34891A

Serial No.

09/765,534

Applicant

Alitalo, K. *et al.*

Filing Date

January 19, 2001

Group

1644

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C120	Lozzio <i>et al.</i> , "Human Chronic Myelogenous Leukemia Cell-Line With Positive Philadelphia Chromosome," <i>Blood</i> , 45(3):321-334 (March, 1975).
C121	Lyman <i>et al.</i> , "Molecular Cloning of a Ligand for the flt3/flk-2 Tyrosine Kinase Receptor: A Proliferative Factor for Primitive Hematopoietic Cells," <i>Cell</i> , 75:1157-1167 (December 17, 1993).
C122	Lymboussaki, A. <i>et al.</i> , "Expression of the Vascular Endothelial Growth Factor C Receptor VEGFR-3 in Lymphatic Endothelium of the Skin and in Vascular Tumors," <i>American Journal of Pathology</i> , 153(2):395-403 (August, 1998).
C123	Makela <i>et al.</i> , "Plasmid pLTRpoly: a Versatile High-Efficiency Mammalian Expression Vector," <i>Gene</i> , 118:293-294 (1992).
C124	Mandriota, S. J. <i>et al.</i> , "Vascular Endothelial Growth Factor-C-Mediated Lymphangiogenesis Promotes Tumour Metastasis," <i>EMBO J.</i> , 20(5): 672-82 (February 15, 2001).
C125	Marchio, S., <i>et al.</i> , "Vascular Endothelial Growth Factor-C Stimulates the Migration and Proliferation of Kaposi's Sarcoma Cells," <i>J. Biol. Chem.</i> , 274(39):27617-22 (September 24, 1999).
C126	Marconcini, L., <i>et al.</i> , "c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis <i>in vivo</i> and <i>in vitro</i> ," <i>Proc. Natl. Acad. Sci. USA</i> , 96:9671-76 (August 1999).
C127	Martin <i>et al.</i> , "HEL Cells: A New Human Erythroleukemia Cell Line With Spontaneous Induced Globin Expression," <i>Science</i> , 216:1233-1235 (1982).
C128	Matthews <i>et al.</i> , "A Receptor Tyrosine Kinase cDNA Isolated From a Population of Enriched Primitive Hematopoietic Cells and Exhibiting Close Genetic Linkage to <i>c-kit</i> ," <i>Proc. Natl. Acad. Sci. USA</i> , 88(20):9026-9030 (October, 1991).
C129	Matthews <i>et al.</i> , "A Receptor Tyrosine Kinase Specific to Hematopoietic Stem and Progenitor Cell-Enriched Populations," <i>Cell</i> , 65(7):1143-1152 (June 28, 1991).

EXAMINER

DATE CONSIDERED


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
28967/34891ASerial No.  
09/765,534Applicant  
Alitalo, K. *et al.*Filing Date  
January 19, 2001Group  
1644

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)



RECEIVED

APR 29 2002

TECH CENTER 1600/2900

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C130	McCutchan <i>et al.</i> , "Enhancement of the Infectivity of Simian Virus 40 Deoxyribonucleic Acid with Diethylaminoethyl-Dextran," <i>J. Natl. Cancer Inst.</i> , 41:351-357 (1968).
C131	Metzelaar <i>et al.</i> , "CD63 Antigen," <i>J. Biol. Chem.</i> , 266(5):3239-3245 (February 15, 1991).
C132	Millauer <i>et al.</i> , "High Affinity VEGF Binding and Developmental Expression Suggest Flk-1 as a Major Regulator of Vasculogenesis and Angiogenesis," <i>Cell</i> , 72:835-846 (March 26, 1993).
C133	Minowada <i>et al.</i> , "Brief Communication: Rosette-Forming Human Lymphoid Cell Lines: Establishment and Evidence for Origin of Thymus-Derived Lymphocytes," <i>J. Natl. Cancer Inst.</i> , 49:891-895 (1972).
C134	Mollinedo <i>et al.</i> , "Early and Selective Induction of Apoptosis in Human Leukemic Cells By the Alkyl-Lysophospholipid ET-18-OCH <sub>3</sub> ," <i>Biochem. &amp; Biophys. Res. Comm.</i> , 192(2):603-609 (April 30, 1993).
C135	Moriyama, M., <i>et al.</i> , "Immunohistochemical Study of Tumour Angiogenesis in Oral Squamous Cell Carcinoma," <i>Oral Oncol.</i> , 33(5):369-74 (September 1997).
C136	Moroni <i>et al.</i> , "EGF-R Antisense RNA Blocks Expression of the Epidermal Growth Factor Receptor and Suppresses the Transforming Phenotype of a Human Carcinoma Cell Line," <i>J. Biol. Chem.</i> , 267(5):2714-2722 (February 5, 1992).
C137	Morrison, S.L. <i>et al.</i> , "Genetically Engineered Antibody Molecules," <i>Advances in Immunology</i> , 44:65-92 (1989).
C138	Mortimer, P. S., "The Pathophysiology of Lymphedema," <i>Cancer</i> , 83 (12 Suppl American):2798-802 (1998).
C139	Moshakis, V. <i>et al.</i> , "Localization of human breast-carcinoma xenografts using antibodies to carcinoembryonic antigen," <i>Br. J. Cancer</i> , 43:575-581 (1981).
C140	Mukkala <i>et al.</i> , "The Synthesis and Use of Activated N-Benzyl Derivatives of Diethylenetriaminetetraacetic Acids: Alternative Reagents for Labeling of Antibodies with Metal Ions," <i>Annal. Biochem.</i> , 176:319-325 (1989).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark Office

Docket No.

28967/34891A

Serial No.

09/765,534

Applicant

Alitalo, K. *et al.*

Filing Date


January 19, 2001

Group

1644

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

RECEIVED  
APR 29 2002

TECH CENTER 1600/2900

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C141	Mustonen <i>et al.</i> , "Endothelial Receptor Tyrosine Kinases Involved in Angiogenesis," <i>J. Cell Biology</i> , 129(4):895-898 (1995).
C142	Nathanson, S.D., <i>et al.</i> , "Microvessels That Predict Axillary Lymph Node Metastases in Patients With Breast Cancer," <i>Arch Surg</i> , 135(5):586-93 (May 2000).
C143	Nicosia, R.F., "What Is the Role of Vascular Endothelial Growth Factor-Related Molecules in Tumor Angiogenesis?" <i>Am. J. Pathol</i> , 153(1):11-6 (July 1998).
C144	Niki, T., <i>et al.</i> , "Expression of Vascular Endothelial Growth Factors A, B, C, and D and Their Relationships to Lymph Node Status in Lung Adenocarcinoma," <i>Clin. Cancer Res.</i> , 6(6):2431-9 (June 2000).
C145	Niki, T. <i>et al.</i> , "Expression of Vascular Endothelial Growth Factor Receptor 3 in Blood and Lymphatic Vessels of Lung Adenocarcinoma," <i>J. Pathol.</i> , 193(4): 450-7 (April, 2001).
C146	Nowell <i>et al.</i> , "Chromosome Studies in Preleukemic States: Myeloproliferative versus Cytopenic Disorders," <i>Cancer</i> , 42:2254-2260 (1978).
C147	Oelrichs <i>et al.</i> , "NYK/FLK-1: A Putative Receptor Protein Tyrosine Kinase Isolated From E10 Embryonic Neuroepithelium is Expressed in Endothelial Cells of the Developing Embryo," <i>Oncogene</i> , 8(1):11-18 (January, 1993).
C148	Oh <i>et al.</i> , "VEGF and VEGF-C: Specific Induction of Angiogenesis and Lymphangiogenesis in the Differentiated Avian Chorioallantoic Membrane," <i>Developmental Biology</i> , 188:96-109 (1997).
C149	Ohta, Y., <i>et al.</i> , "Increased Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor-C and Decreased NM23 Expression Associated with Microdissemination in the Lymph Nodes in Stage 1 Non-Small Cell Lung Cancer," <i>J. Thorac Cardiovasc Surg</i> , 119(4 Pt 1):804-13 (April 2000).
C150	Ohta, Y., <i>et al.</i> , "VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours," <i>Br. J. Cancer</i> , 81(1):54-61 (September 1999).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark OfficeAtt. Docket No.  
28967/34891ASerial No.  
09/765,534Applicant  
Alitalo, K. *et al.*Filing Date  
January 19, 2001Group  
1644

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C151	O'Reilly, M.S. <i>et al.</i> , "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma," <i>Cell</i> , 79(2):315-328 (October, 1994).
C152	O'Reilly, M.S. <i>et al.</i> , "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth," <i>Cell</i> , 88(2):277-285 (January, 1997).
C153	Padlan, E.A., "A Possible Procedure For Reducing The Immunogenicity Of Antibody Variable Domains While Preserving Their Ligand-Binding Properties," <i>Molecular Immunology</i> , 28(4/5):489-498 (1991).
C154	Pajusola <i>et al.</i> , "FLT4 Receptor Tyrosine Kinase Contains Seven Immunoglobulin-Like Loops and is Expressed in Multiple Human Tissues and Cell Lines," <i>Cancer Research</i> , 52(20):5738-5743 (October 15, 1992).
C155	Pajusola <i>et al.</i> , "Two Human FLT4 Receptor Tyrosine Kinase Isoforms With Distinct Carboxy Terminal Tails are Produced by Alternative Processing of Primary Transcripts," <i>Oncogene</i> , 8:2931-2937 (1993).
C156	Pajusola, "Cloning and Characterization of a New Endothelial Receptor Tyrosine Kinase FLT4 and Two Novel VEGF-Like Growth Factors VEGF-B and VEGF-C," Molecular/Cancer Biology Laboratory and Department of Pathology, Haartman Institute and Department of Biosciences, Division of Genetics, University of Helsinki, Academic Dissertation, Helsinki 1996.
C157	Pajusola <i>et al.</i> , "Signalling Properties of FLT4, a Proteolytically Processed Receptor Tyrosine Kinase Related To Two VEGF Receptors," <i>Oncogene</i> , 9:3545-3555 (1994).
C158	Parker, S. H., <i>et al.</i> , "Identification of the Sentinel Node in Patients With Breast Cancer," <i>Radiol Clin North Am</i> , 38(4):809-23 (2000).
C159	Partanen <i>et al.</i> , "Putative Tyrosine Kinases Expressed in K-562 Human Leukemia Cells," <i>Proc. Nat'l Acad. Sci., USA</i> , 87(22):8913-8917 (November, 1990).
C160	Partanen <i>et al.</i> , "A Novel Endothelial Cell Surface Receptor Tyrosine Kinase with Extracellular Epidermal Growth Factor Homology Domains," <i>Mol. Cell. Biol.</i> , 12(4):1698-1707 (April, 1992).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

28967/34891A

Serial No.

09/765,534

Applicant

Alitalo, K. *et al.*

Filing Date

January 19, 2001

Group

1644

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C161	Partanen, T.A., <i>et al.</i> , "Lack of Lymphatic Vascular Specificity of Vascular Endothelial Growth Factor Receptor 3 in 185 Vascular Tumors," <i>Cancer</i> , 86(11): 2406-12 (December 1, 1999).
C162	Patent Cooperation Treaty Search Report for PCT/US 99/23525
C163	Paulsson, G. <i>et al.</i> , "The Balbiani Ring 3 Gene in Chironomus Tentans Has a Diverged Repetitive Structure Split by Many Introns," <i>J. Mol. Biol.</i> , 211:331-49 (1990)
C164	Pepper, M. S., "Lymphangiogenesis and Tumor Metastasis: Myth or Reality?," <i>Clinical Cancer Res.</i> , 7: 462-68 (March, 2001).
C165	Perumov <i>et al.</i> , "Influence of Antisense RNA's of Interleukin-1 $\beta$ and Interleukin-1 Receptor Antagonist on Interleukin-1 $\beta$ Production," <i>J. Cell. Biochem., Supplement</i> , 16 pt B:285 (ABSTRACT J216) (1992).
C166	Peters <i>et al.</i> , "Vascular Endothelial Growth Factor Receptor Expression During Embryogenesis and Tissue Repair Suggests a Role in Endothelial Differentiation and Blood Vessel Growth," <i>Proc. Nat'l Acad. Sci., USA</i> , 90:8915-8919 (October, 1993).
C167	Peterson, C. and Legerski, R., "High-frequency Transformation of Human Repair-deficient Cell Lines by an Epstein-Barr Virus-based cDNA Expression Vector," <i>Gene</i> , 107: 279-84, (1991).
C168	Pietersz <i>et al.</i> , "Antibody Conjugates for the Treatment of Cancer," <i>Immunological Reviews</i> , 129:57-80 (1992).
C169	Plückthun, A. <i>et al.</i> , "New protein engineering approaches to multivalent and bispecific antibody fragments," <i>Immunotechnology</i> , 3:83-105 (1997).
C170	Poncz <i>et al.</i> , "Cloning and Characterization of Platelet Factor 4 cDNA Derived From a Human Erythroleukemic Cell Line," <i>Blood</i> , 69(1):219-223 (January, 1987).
C171	Rader, C. <i>et al.</i> , "Phage Display of Combinatorial Antibody Libraries," <i>Curr. Opin. Biotech.</i> , 8:503-508 (1997).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

28967/34891A

Serial No.

09/765,534

Applicant

Alitalo, K. *et al.*

Filing Date

January 19, 2001

Group

1644

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C172	Reedijk <i>et al.</i> , "Tyr721 Regulates Specific Binding of the CSF-1 Receptor Kinase Insert to P1 3'-Kinase SH2 Domains: a Model for SH2-Mediated Receptor-Target Interactions," <i>EMBO J.</i> , 11(4):1365-1372 (1992).
C173	Relf, M. <i>et al.</i> , "Expression of the Angiogenic Factors Vascular Endothelial Cell Growth Factor, Acidic and Basic Fibroblast Growth Factor, Tumor Growth Factor $\beta$ -1, Platelet-derived Endothelial Cell Growth Factor, Placenta Growth Factor, and Pleiotrophin in Human Primary Breast Cancer and Its Relation to Angiogenesis," <i>Cancer Research</i> , 57:963-969 (March, 1997).
C174	Renner, C. <i>et al.</i> , "Tumor Therapy by Immune Recruitment with Bispecific Antibodies," <i>Immunological Reviews</i> , No.145, pp. 179-209 (1995).
C175	Riechmann, L. <i>et al.</i> , "Reshaping human antibodies for therapy," <i>Nature</i> , 332(6162):323-327 (March, 1988).
C176	Roitt, M., "Essential Immunology," Blackwell Scientific Pub., Oxford, pp.65-68 & 74 (1991).
C177	Rosnet <i>et al.</i> , "Isolation and Chromosomal Localization of a Novel FMS-Like Tyrosine Kinase Gene," <i>Oncogene</i> , 6(9):1641-1650 (1991).
C178	Rosnet <i>et al.</i> , "Murine <i>Flt3</i> , a Gene Encoding a Novel Tyrosine Kinase Receptor of the PDGFR/CSF1R Family," <i>Genomics</i> , 9:380-385 (1991).
C179	Saaristo, A., <i>et al.</i> , "Vascular Endothelial Growth Factor-C and its Receptor VEGFR-3 in the Nasal Mucosa and in Nasopharyngeal Tumors," <i>Am. J. Pathology</i> , 157(1):7-14 (July 2000).
C180	Sabin, F.R., "The Lymphatic System in Human Embryos, with Consideration of the Morphology of the System as a Whole," <i>Am. J. Anat.</i> , 9(1):43-91 (1909).
C181	Salven, P. <i>et al.</i> , "Vascular Endothelial Growth Factors VEGF-B and VEGF-C Are Expressed in Human Tumors," <i>American J. Pathology</i> , 153(1):103-108 (July, 1998).
C182	Sambrook <i>et al.</i> , <i>Molecular Cloning: A Laboratory Manual</i> , Cold Spring Harbor Laboratory Press, pp. 2.60-2.70, 4.21-4.32, 7.3-7.36 (1989).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

APR 29 2002

TECH CENTER 1600/2900

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

28967/34891A

Serial No.

09/765,534

Applicant

Alitalo, K. *et al.*

Filing Date

January 19, 2001

Group

1644

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C183	Sato and Seiki, "Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells," <i>Oncogene</i> , 8:395-405 (1993).
C184	Satoh <i>et al.</i> , "Regional Localization of the Human <i>c-ros</i> -1 on 6q22 and <i>flt</i> on 13q12," <i>Jpn. J. Cancer Res.</i> , 78:772-775 (1987).
C185	Schlessinger, J., "Cell Signaling by Receptor Tyrosine Kinases," <i>Cell</i> , 103(2): 211-25 (October 13, 2000).
C186	Schneider <i>et al.</i> , "A One-step Purification of Membrane Proteins Using a High Efficiency Immunomatrix," <i>J. Biol. Chem.</i> , 257(18):10766-10769 (September 25, 1982).
C187	Schreiber <i>et al.</i> , "Interaction of endothelial cell growth factor with heparin: Characterization by receptor and antibody recognition," <i>Proc. Nat'l Acad. Sci.</i> , 82:6138-6142 (September, 1985).
C188	Schwenk <i>et al.</i> , "Cell Cycle Dependency of a T-Cell Marker on Lymphoblasts," <i>Blut</i> , 31:299-306 (1975).
C189	Scott, P.A.E. <i>et al.</i> , "Laboratory-Clinic Interface: Current approaches to targeting cancer using antiangiogenesis therapies," <i>Cancer Treatment Reviews</i> , 20:393-412 (1994).
C190	Segal, D.M. <i>et al.</i> , "Alternative Triggering Molecules and Single Chain Bispecific Antibodies," <i>Journal of Hematotherapy</i> , 4:377-382 (1995).
C191	Segal, D.M. <i>et al.</i> , "Targetting of Anti-Tumor Responses with Bispecific Antibodies," <i>Immunobiology</i> , 185(2-4):390-402 (August, 1992).
C192	Sherr <i>et al.</i> , "The <i>c-fms</i> Proto-Oncogene Product is Related to the Receptor for the Mononuclear Phagocyte Growth Factor, CSF-1," <i>Cell</i> , 41:665-676 (July, 1985).
C193	Shi <i>et al.</i> , "16-Kilodalton Heparin Binding (Fibroblast) Growth Factor Type One Appears in a Stable 40-Kilodalton Complex After Receptor-Dependent Internalization," <i>J. Biol. Chem.</i> , 266(9):5774-5779 (March 25, 1991).

EXAMINER

DATE CONSIDERED


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
28967/34891ASerial No.  
09/765,534Applicant  
Alitalo, K. *et al.*Filing Date  
January 19, 2001Group  
1644

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)



RECEIVED

APR 29 2002

TECH CENTER 1600/2900

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C194	Shibuya <i>et al.</i> , "Nucleotide Sequence and Expression of a Novel Human Receptor-Type Tyrosine Kinase Gene ( <i>flt</i> ) Closely Related to the <i>fms</i> Family," <i>Oncogene</i> , 5:519-524 (1990).
C195	Shibuya, M., "Role of VEGF-FLT Receptor System in Normal and Tumor Angiogenesis," <i>Advances in Cancer Research</i> , 67:281-316 (1995).
C196	Shushanov, S., <i>et al.</i> , "VEGFc and VEGFR3 Expression in Human Thyroid Pathologies," <i>Int. J. Cancer</i> , 86:47-52 (2000).
C197	Skobe, M., <i>et al.</i> , "Vascular Endothelial Growth Factor-C (VEGF-C) and its Receptors KDR and flt-4 are Expressed in AIDS-Associated Kaposi's Sarcoma," <i>J. Invest. Dermatology</i> , 113:1047-1053 (1999).
C198	Skobe, M. <i>et al.</i> , "Induction of Tumor Lymphangiogenesis by VEGF-C Promotes Breast Cancer Metastasis," <i>Nat. Med.</i> , 7(2): 192-8 (February, 2001).
C199	Sowter, H.M., <i>et al.</i> , "Expression and Localization of the Vascular Endothelial Growth Factor Family in Ovarian Epithelial Tumors," <i>Lab. Invest.</i> , 77(6):607-14 (December 1997).
C200	Stacey <i>et al.</i> , "SVpoly: A Versatile Mammalian Expression Vector," <i>Nucl. Acids Res.</i> , 18(9):2829 (1990).
C201	Stacker, S. A., "VEGF-D Promotes the Metastatic Spread of Tumor Cells Via the Lymphatics," <i>Nat. Med.</i> , 7(2): 186-91 (February, 2001).
C202	Staunton <i>et al.</i> , "The Arrangement of the Immunoglobulin-Like Domains of ICAM-1 and the Binding Sites for LFA-1 and Rhinovirus," <i>Cell</i> , 61:243-254 (April 20, 1990).
C203	Stenman <i>et al.</i> , "Human PDGFA Receptor Gene Maps to the Same Region on Chromosome 4 as the KIT Oncogene," <i>Genes, Chromosomes, Cancer</i> , 1:155-158 (1989).
C204	Stohrer <i>et al.</i> , "Oncotic Pressure in Solid Tumors is Elevated," <i>Cancer Res.</i> , 60: 4251-5, (2000).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
28967/34891ASerial No.  
09/765,534Applicant  
Alitalo, K. *et al.*Filing Date  
January 19, 2001Group  
1644

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)



RECEIVED

APR 29 2002

TECH CENTER 1600/2900

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C205	Sundström <i>et al.</i> , "Establishment and Characterization of a Human Histiocytic Lymphoma Cell Line (U-937)," <i>Int. J. Cancer</i> , 17:565-577 (1976).
C206	Swolin <i>et al.</i> , "On the 5q-Deletion: Clinical and Cytogenetic Observations in Ten Patients and Review of the Literature," <i>Blood</i> , 58:986-993 (1981).
C207	Taipale, J. <i>et al.</i> , "Vascular Endothelial Growth Factor Receptor-3," <i>Curr Top Microbiol Immunol.</i> , 237:85-96 (1999).
C208	Tang, R. F. <i>et al.</i> , "Overexpression of Lymphangiogenesis Growth Factor VEGF-C in Human Pancreatic Cancer," <i>Pancreas</i> , 22(3): 285-92 (April, 2001).
C209	Tekmal, R.R. <i>et al.</i> , "A Novel in Vitro and in Vivo Breast Cancer Model for Testing Inhibitors of Estrogen Biosynthesis and Its Action Using Mammary Tumor Cells With an Activated int-5/aromatase Gene," <i>Cancer Letters</i> , 118(1):21-28 (September, 1997).
C210	Tempest, P.R. <i>et al.</i> , "Reshaping a Human Monoclonal Antibody to Inhibit Human Respiratory Syncytial Virus Infection <i>in Vivo</i> ," <i>BioTechnology</i> , 9(3):266-271 (March, 1991).
C211	Terman <i>et al.</i> , "Identification of a New Endothelial Cell growth Factor Receptor Tyrosine Kinase," <i>Oncogene</i> , 6(9):1677-1683 (1991).
C212	Terman <i>et al.</i> , "Identification of the KDR Tyrosine Kinase as a Receptor for Vascular Endothelial Cell Growth Factor," <i>Biochem &amp; Biophys. Res. Comm.</i> , 187(3):1579-1586 (September 30, 1992).
C213	Thompson <i>et al.</i> , "Cloned Human Teratoma Cells Differentiate into Neuron-Like Cells and Other Cell Types in Retinoic Acid," <i>J. Cell Sci.</i> , 72:37-64 (1984).
C214	Thurston, G. <i>et al.</i> , "Leakage-resistant Blood Vessels in Mice Transgenically Overexpressing Angiopoietin-1," <i>Science</i> , 286(5449):2511-4 (1999).
C215	Tomiyasu <i>et al.</i> , "Long Arm Deletion of Chromosome No. 5 in a Case of Philadelphia Chromosome-Positive Chronic Myelocytic Leukemia," <i>Cancer Genet. Cytogenet.</i> , 2:309-315 (1980).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

28967/34891A

Serial No.

09/765,534

Applicant

Alitalo, K. *et al.*

Filing Date

January 19, 2001

Group

1644

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)


## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C216	Tortora <i>et al.</i> , "Differentiation of HL-60 Leukemia By Type I Regulatory Subunit Antisense Oligodeoxynucleotide of a cAMP-Dependent Protein Kinase," <i>Proc. Nat'l Acad. Sci., USA</i> , 88(5):2011-2015 (March, 1991).
C217	Traunecker, A. <i>et al.</i> , "Myeloma based expression system for production of large mammalian proteins," <i>Trends in BioTechnology</i> , 9(4):109-113 (April, 1991).
C218	Tsurusaki, T., <i>et al.</i> , "Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis," <i>Br. J. Cancer</i> , 80(2):309-313 (1999).
C219	Ullrich <i>et al.</i> , "Signal Transduction By Receptors with Tyrosine Kinase Activity," <i>Cell</i> , 61:203-212 (April 20, 1990).
C220	Valtola, R., <i>et al.</i> , "VEGFR-3 and Its Ligand VEGF-C Are Associated with Angiogenesis in Breast Cancer," <i>Am. J. Pathol.</i> , 154(5):1381-90 (May 1999).
C221	van der Putte, S.C.J., "The Development of the Lymphatic System in Man," <i>Adv. Anat. Embryol. Cell Biol.</i> , 51:3 (1975).
C222	Van Den Berghe <i>et al.</i> , "Distinct Haematological Disorder with Deletion of Long Arm of No. 5 Chromosome." <i>Nature</i> , 251:437-439 (1974).
C223	Van Den Berghe <i>et al.</i> , "Transformation of Polycythemia Vera to Myelofibrosis and Late Appearance of a 5q-Chromosome Anomaly," <i>Cancer Genet. Cytogenet.</i> , 1:157-162 (1979).
C224	Van Hinsberg <i>et al.</i> , "Effect of Thrombin on the Production of Plasminogen Activators and PA Inhibitor-1 by Human Foreskin Microvascular Endothelial Cells," <i>Thromb. Haemostas.</i> , 57(2):148-153 (1987).
C225	Van Hinsberg <i>et al.</i> , "Production of Plasminogen Activators and Inhibitors by Serially Propagated Endothelial Cells From Adult Human Blood Vessels," <i>Arteriosclerosis</i> , 7:389-400 (July/August, 1987).
C226	Veikkola, T., <i>et al.</i> , "Regulation of Angiogenesis Via Vascular Endothelial Growth Factor Receptors," <i>Cancer Res.</i> , 60(2):203-12 (2000).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 28967/34891A	Serial No. 09/765,534
<b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)		Applicant Alitalo, K. <i>et al.</i>	Filing Date January 19, 2001	Group 1644

RECEIVED

APR 29 2002

TECH CENTER 1600/2900

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
	C227	Verhoeven, M. <i>et al.</i> , "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," <i>Science</i> , 239:1534-1536 (March, 1988).
	C228	Wang, "Signal Transduction in Human Hematopoietic Cells by Vascular Endothelial Growth Factor Related Protein, a Novel Ligand for the FLT4 Receptor," <i>Blood</i> , 90(9):3507-3515 (November, 1997).
	C229	Warrington <i>et al.</i> , "Radiation of Hybrid Map of 13 Loci on the Long Arm of Chromosome 5," <i>Genomics</i> , 11:701-708 (1991).
	C230	Weidner, N. <i>et al.</i> , "Tumor Angiogenesis: A New Significant and Independent Prognostic Indicator in Early-Stage Breast Carcinoma," <i>J. Natl. Cancer Inst.</i> , 84(24):1875-1887 (December, 1992).
	C231	Wen, D. <i>et al.</i> , "New Differentiation Factor: A Transmembrane Glycoprotein Containing an EGF Domain and an Immunoglobulin Homology Unit," <i>Cell</i> , 69:559-572 (May 1, 1992).
	C232	Weninger, W., <i>et al.</i> , "Expression of Vascular Endothelial Growth Factor Receptor-3 and Podoplanin Suggests a Lymphatic Endothelial Cell Origin of Kaposi's Sarcoma Tumor Cells," <i>Lab. Invest.</i> , 79(2):243-51 (February 1999).
	C233	Whang-Peng <i>et al.</i> , "Cytogenic Studies in Patients With Myelofibrosis and Myeloid Metaplasia," <i>Leuk. Res.</i> , 2:41-48 (1978).
	C234	Wilkinson <i>et al.</i> , "Expression of the Proto-Oncogene int-1 is Restricted to Specific Neural Cells in the Developing Mouse Embryo," <i>Cell</i> , 50:79-88 (1987).
	C235	Williams, A.F. and Barclay, A.N., "The Immunoglobulin Superfamily-Domains for Cell Surface Recognition," <i>Ann. Rev. Immunol.</i> , 6:381-405 (1988).
	C236	Williams, J.C. <i>et al.</i> , "N-methyl-N-nitrosourea-Induced Rat Mammary Tumors. Hormonal Responsiveness but Lack of Spontaneous Metastasis," <i>J. Nat. Cancer Inst.</i> , 66(1):147-155 (January, 1981).
	C237	Witte <i>et al.</i> , "Lymphangiogenesis: Mechanisms, Significance and Clinical Implications," in Regulation of Angiogenesis (eds. Goldberg, I.D. & Rosen, E. M.) 65-112 (birkhauser Verlag, Basel, Switzerland) 1997.

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
28967/34891ASerial No.  
09/765,534Applicant  
Alitalo, K. *et al.*Filing Date  
January 19, 2001Group  
1644

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)


## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C238	Witzenbichler, B., <i>et al.</i> , "Vascular Endothelial Growth Factor-C (VEGF-C/VEGF-2) Promotes Angiogenesis in the Setting of Tissue Ischemia," <i>American Journal of Pathology</i> , Vol. 153, No.2:381-394 (August 1998).
C239	Yamaguchi <i>et al.</i> , " <i>Flk-1</i> , an <i>Flt</i> -Related Tyrosine Kinase is an Early Marker for Endothelial Cell Precursors," <i>Development</i> , 118:489-498 (1993).
C240	Yarden <i>et al.</i> , "Human Proto-Oncogene c-kit: A New Cell Surface Receptor Tyrosine Kinase for an Unidentified Ligand," <i>EMBO J.</i> , 6(11):3341-3351 (1987).
C241	Ylänné <i>et al.</i> , "Platelet Glycoprotein IIb/IIIa Complex in Cultured Cells: Localization in Focal Adhesion Sites in Spreading HEL Cells," <i>Blood</i> , 72: 1478-1486 (1988).
C242	Yokoyama, Y., <i>et al.</i> , "Prognostic Significance of Vascular Endothelial Growth Factor and Its Receptors in Endometrial Carcinoma," <i>Gyn. Oncology</i> 77:413-418 (2000).
C243	Yonemura, Y., <i>et al.</i> , "Role of Vascular Endothelial Growth Factor C Expression in the Development of Lymph Node Metastasis in Gastric Cancer," <i>Clin. Cancer Res.</i> , 5:1823-1829 (July 1999).
C244	Yonemura, Y. <i>et al.</i> , "Lymphangiogenesis and the Vascular Endothelial Growth Factor Receptor (VEGFR)-3 in Gastric Cancer," <i>Eur. J. Cancer</i> , 37(7): 918-23 (May, 2001).
C245	Dias, <i>et al.</i> , "Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy," <i>Blood</i> , 99:2179-2184 (2002)
C246	Karkkainen, <i>et al.</i> , "Lymphatic endothelium: a new frontier of metastasis research," <i>Nat. Cell. Biol.</i> 4:E2-E5 (2002)
C247	Makinen, <i>et al.</i> , "Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3," <i>Nat. Med.</i> 7:199-205 (2001)
C248	Mattila, <i>et al.</i> , "VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors," <i>Int. J. Cancer</i> 98:946-951 (2002)

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 28967/34891A	Serial No. 09/765,534
<b>INFORMATION DISCLOSURE STATEMENT</b> <i>(Use several sheets if necessary)</i>		Applicant Alitalo, K. <i>et al.</i>		
		Filing Date January 19, 2001	Group 1644	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
C249	Siemeister, <i>et al.</i> , "Two Independent Mechanisms Essential for Tumor Angiogenesis: Inhibition of Human Melanoma Xenograft Growth by Interfering With Either the Vascular Endothelial Growth Factor Receptor Pathway or the Tie-2 Pathway," <i>Cancer Res.</i> 59:3185-91 (1999)	
C250	Witmer, <i>et al.</i> , "VEGFR-3 in adult angiogenesis," <i>J. Path.</i> 195:490-497 (2001)	

RECEIVED  
 APR 29 2002  
 TECH CENTER 1600/2900

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.	